Antihypertensive effect of ragaglitazar: A novel PPARα and γ dual activator

Pharmacological Research

Volumn 54, Issue 2, 2006, Pages 129-135

  Mamnoor, Prem K ^a   Hegde, Pragathi ^a   Datla, Srinivas R ^a   Damarla, Ravi K B ^a   Rajagopalan, Ramanujam ^a   Chakrabarti, Ranjan ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Hypertension; Peroxisome proliferators activated receptor (PPAR); Ragaglitazar

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAGAGLITAZAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; INSULIN RESISTANCE; MALE; OXAZINES; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; RATS, INBRED STRAINS; RATS, INBRED WKY; RATS, ZUCKER; REFERENCE STANDARDS; TRIGLYCERIDES; VASODILATOR AGENTS;

EID: 33745872554     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.020     Document Type: Article

References (51)

1. Berger J., and Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 53 (2002) 409-435
2. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
3. Lohray B.B., Lohray V.B., Bajji A.C., Kalchar S., Poondra R.R., Padakanti S., et al. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 44 (2001) 2675-2678
4. Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140 (2003) 527-537
5. Saad M.F., et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27 (2004) 1324-1329
6. Stumvoll M., Haring H.U., De Vriese A.S., Verbeuren T.J., Van de Voorde J., and Lameire N.H. Glitazones: clinical effects and molecular mechanisms. Ann Med 34 (2002) 217-224
7. Epstein M., and Sowers J.R. Diabetes mellitus and hypertension. Hypertension 19 (1992) 403-418
8. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., and Vanhoutte P.M. Endothelial dysfunction in diabetes. Br J Pharmacol 130 (2000) 963-974
9. Barroso I., Gurnell M., Crowley V.E., Agostini M., Schwabe J.W., Soos M.A., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Hypertension 402 (1999) 880-883
10. Gerber P., Lubben G., Heusler S., and Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomized study in patients with type 2 diabetes mellitus. Curr Med Res Opin 19 (2003) 532-539
11. Idzior-Walus B. Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome. Przegl Lek 58 (2001) 924-927
12. Schiffrin E.L., Amiri F., Benkirane K., Iglarz M., and Diep Q.N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42 (2003) 664-668
13. Wierzbicki A.S. Lipid lowering: another method of reducing blood pressure?. J Hum Hypertension 16 (2002) 753-760
14. Torok J., Babal P., Matuskova J., Luptak I., Klimes I., and Simko F. Impaired endothelial function of thoracic aorta in hereditary hypertriglyceridemic rats. Ann NY Acad Sci 967 (2002) 469-475
15. Velliquette R.A., Friedman J.E., Shao J., Zhang B.B., and Ernsberger P. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 314 1 (2005) 422-430
16. Walker A.B., Chattington P.D., Buckingham R.E., and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 (1999) 1448-1453
17. Kosegawa I., Chen S., Awata T., Negishi K., and Katayama S. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats. Clin Exp Hypertens 21 (1999) 199-211
18. Uchida A., Nakata T., Hatta T., Kiyama M., Kawa T., Morimoto S., et al. Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 61 4 (1997) 455-464
19. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 1 (2004) 48-56
20. Iglarz M., Touyz R.M., Amiri F., Lavoie M.F., Diep Q.N., and Schiffrin E.L. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23 1 (2003) 45-51
21. Shatara R.K., Quest D.W., and Wilson T.W. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol 78 5 (2000) 367-371
22. Grinsell J.W., Lardinois C.K., Swislocki A., Gonzalez R., Sare J.S., Michaels J.R., et al. Pioglitazone attenuates basal and post-prandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 13 4 Pt 1 (2000) 370-375
23. Diep Q.N., and Schiffrin E.L. Increased expression of peroxisome proliferator-activated receptor-alpha and -gamma in blood vessels of spontaneously hypertensive rats. Hypertension 38 (2001) 249-254
24. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96 1 (1995) 354-360
25. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 3 (2004) 661-666
26. Khan M.A., St Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002) 708-711
27. Sigmon D.H., and Beierwaltes W.H. Endothelium-derived constricting factor in renovascular hypertension. Hypertension 25 (1995) 803-808
28. Chakrabarti R., Vikramadithyan R.K., Kumar M.P., Kumar S.K., Mamidi N.V., Misra P., et al. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes Metab 4 (2002) 319-328
29. Walker A.B., Dores J., Buckingham R.E., Savage M.W., and Williams G. Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci (Lond) 93 (1997) 235-241
30. Zemel M.B., Reddy S., and Sowers J.R. Insulin attenuation of vasoconstrictor responses to phenylephrine in Zucker lean and obese rats. Am J Hypertens 4 (1991) 537-539
31. Reaven G.M., and Banting lecture. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
32. Hsueh W.A., and Quinones M.J. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 92 (2003) 10J-17J
33. Lynn M.A., Rupnow H.L., Kleinhenz D.J., Kanner W.A., Dudley S.C., and Hart C.M. Fatty acids differentially modulate insulin-stimulated endothelial nitric oxide production by an Akt-independent pathway. J Investig Med 52 (2004) 129-136
34. Sowers J.R., Epstein M., and Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37 (2001) 1053-1059
35. Herz M., Johns D., Reviriego J., Grossman L.D., Godin C., Duran S., et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 25 (2003) 1074-1095
36. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
37. Moller D.E., and Berger J.P. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27 (2003) S17-S21
38. Pickavance L.C., Brand C.L., Wassermann K., and Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144 3 (2005) 308-316
39. Verma S., Bhanot S., Arikawa E., Yao L., and McNeill J.H. Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 56 (1998) 7-16
40. Brandt J.M., Djouadi F., and Kelly D.P. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem 273 (1998) 23786-23792
41. Landmesser U., Hornig B., and Drexler H. Endothelial function: a critical determinant in atherosclerosis. Circulation 109 (2004) II27-II33
42. Mineo C., and Shaul P.W. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 13 (2003) 226-231
43. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., and Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28 6 (2005) 1419-1424
44. Alonso-Galicia M., Brands M.W., Zappe D.H., and Hall J.E. Hypertension in Obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28 (1996) 1047-1054
45. Bolterman R.J., Manriquez M.C., Ruiz M.C.O., Juncos L.A., and Romero J.C. Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats. Hypertension 46 4 (2005) 943-947
46. Kintscher U., Lyon C.J., and Law R.E. Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9 (2004) 359-369
47. Mehta J.L., Hu B., Chen J., and Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 23 (2003) 2203-2208
48. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284 3 (2003) E531-E540
49. Egerod F.L., Nielsen H.S., Iversen L., Thorup I., Storgaard T., and Oleksiewicz M.B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 10 4 (2005) 295-309
50. Oleksiewicz M.B., Thorup I., Nielsen H.S., Andersen H.V., Hegelund A.C., Iversen L., et al. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 33 5 (2005) 552-560
51. Schiffrin E.L., Amiri F., Benkirane K., Iglarz M., and Diep Q.N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42 (2003) 664-668